A novel chimeric antigen receptor (CAR) T-cell therapy induced complete and durable responses in a phase I trial involving patients with heavily...
Myeloma NZ
Gene therapy may help fight tough-to-treat blood cancer
A gene therapy that tweaks the immune system might offer hope to people with blood cancer that has resisted standard treatments, a new preliminary...
20k NZers sign petitions for better funding of medicines
Originally published on Te ao Almost 20,000 New Zealanders have signed eight petitions to be presented to parliament, demanding better funding of...
Researchers discover how to prevent kidney damage in patients with multiple myeloma
Researchers at the University of Alabama at Birmingham have discovered a way to prevent kidney failure from occurring in people with multiple...
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.
The treatment landscape for multiple myeloma has dramatically changed over the past decade with the introduction of several new classes of drugs,...
JOIN THE MARCH
For those who are able to, including family and friends, we urge you to join us on Tuesday 7 May in Wellington to march for the RIGHT TO LIVE. We'll...
Toward personalized treatment in multiple myeloma based on molecular characteristics.
To date, the choice of therapy for an individual multiple myeloma patient has been based on clinical factors such as age and comorbidities. The...
Newsletter: April 2019
Greetings to everyone as the days draw in. We are intending to generate some heat with various planned activities over the next month. There has...
Patient Seminar with Prof. Nikhil C. Munshi: Minimal residual disease in Myeloma sessions
https://vimeo.com/330610777 https://vimeo.com/330611169
Imaging in multiple myeloma: How? When?
Bone disease is the most frequent feature of multiple myeloma (MM) and represents a marker of end-organ damage; it is used to establish the...
Multiple Myeloma Research Review
Highlights include: Real-life safety and efficacy of autologous SCT in elderly MM Lenalidomide maintenance vs. observation for newly diagnosed MM...
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised,...